Form 4: Xencor GC Receives Equity Grants, Sells Shares for Tax

Xencor's SVP and General Counsel, Celia Eckert, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Summary

• Celia Eckert, SVP and General Counsel of Xencor Inc. (XNCR), reported changes in her beneficial ownership.
• On March 2, 2026, Eckert acquired 18,680 restricted stock units (RSUs) at a price of $0 per share.
• These RSUs vest in three equal annual installments, with 1/3 vesting on the first, second, and third anniversaries of the grant date.
• Also on March 2, 2026, Eckert acquired 112,080 stock options with an exercise price of $12.30 per share.
• The stock options vest 25% on the one-year anniversary of the grant date (March 2, 2027), and 1/48th monthly thereafter, becoming fully vested on the four-year anniversary (March 2, 2030).
• On March 3, 2026, Eckert disposed of 1,492 shares of common stock at a price of $11.8951 per share.
• This disposition was made to cover withholding taxes upon the vesting of 3,502 restricted stock units.
• Following these transactions, Eckert directly beneficially owns 81,929 shares of common stock and 112,080 stock options.
• Previous acquisitions included 977 shares on June 10, 2025, and 257 shares on December 10, 2025, through the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive. While a disposition occurred, it was for tax purposes, and the significant equity grants align management incentives with long-term company performance, which is generally favorable for shareholders.

Positives

• The grant of 18,680 restricted stock units and 112,080 stock options aligns management's interests with long-term shareholder value.
• Equity compensation is a standard practice to incentivize executives and retain talent.

Negatives

• A disposition of 1,492 shares of common stock occurred, although it was for tax withholding purposes.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a long-term incentive structure, with shares and options vesting over periods of three and four years, respectively, contingent on continuous service.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to senior executives is a standard component of compensation packages in the biotechnology and pharmaceutical industries. These equity awards are designed to align executive incentives with long-term company performance and shareholder interests, a common practice among Xencor's peers.

Comparison to Industry Standards

• Equity grants of this nature (RSUs and stock options) are typical for senior executives in the biotech sector, comparable to compensation structures seen at companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals, where a significant portion of executive pay is tied to equity performance.
• The vesting schedules (3-year for RSUs, 4-year for options) are standard for retaining talent and encouraging long-term commitment, aligning with industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: The grant of equity awards can lead to minor dilution over time as shares vest, but it also strengthens the alignment of executive interests with shareholder value creation.
• Employees: The Employee Stock Purchase Plan (ESPP) mentioned indicates broader employee participation in company ownership, fostering a sense of shared success.

Next Steps

• Continued service by Celia Eckert to meet vesting conditions for RSUs and stock options.
• Future vesting events for RSUs on March 2, 2027, March 2, 2028, and March 2, 2029.
• Future vesting events for stock options, with 25% vesting on March 2, 2027, and monthly thereafter until fully vested on March 2, 2030.

Key Dates

Recommendation

This Form 4 details routine executive compensation and a tax-related share disposition. It does not present new fundamental information that would alter an investment thesis for Xencor Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Xencor, XNCR, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Beneficial Ownership